Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pachner, A. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pachner, A. R.
Related Collections
Right arrow All Immunology
Right arrow Multiple sclerosis
NEUROLOGY 2003;61:1444-1446
© 2003 American Academy of Neurology
Brief Communications

An improved ELISA for screening for neutralizing anti-IFN-ß antibodies in MS patients

Andrew R. Pachner, MD

From the Department of Neurology and Neurosciences, UMDNJ–New Jersey Medical School, Newark.

Address correspondence and reprint requests to Dr. Andrew R. Pachner, Department of Neurology and Neurosciences, UMDNJ–New Jersey Medical School, 185 S. Orange Ave., Newark, NJ 07103; e-mail: Pachner{at}umdnj.edu

A reliable screening assay for anti-interferon beta (IFNß) antibodies is needed for patients with multiple sclerosis (MS) receiving IFNß therapy. The performance of a new ELISA method, the capture ELISA (cELISA), was assessed by comparing it to a standard IFNß ELISA in correlating with neutralizing antibodies measurement in 453 sera from patients with MS. The cELISA outperformed the standard ELISA, and may be a suitable screening assay for anti-IFNß antibodies in IFNß-treated patients with MS.

Received April 25, 2003. Accepted in final form July 26, 2003.




This article has been cited by other articles:


Home page
 NeurologyHome page
A. R. Pachner, D. Cadavid, L. Wolansky, and J. Skurnick
Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study
Neurology, November 3, 2009; 73(18): 1485 - 1492.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A. R. Pachner, J. D. Warth, A. Pace, S. Goelz, and On behalf of the INSIGHT investigators
Effect of neutralizing antibodies on biomarker responses to interferon beta: The INSIGHT study
Neurology, November 3, 2009; 73(18): 1493 - 1500.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
S. Cepok, H. Schreiber, S. Hoffmann, D. Zhou, O. Neuhaus, G. von Geldern, S. Hochgesand, S. Nessler, V. Rothhammer, M. Lang, et al.
Enhancement of Chemokine Expression by Interferon Beta Therapy in Patients With Multiple Sclerosis
Arch Neurol, October 1, 2009; 66(10): 1216 - 1223.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
C Gneiss, M Brugger, A Millonig, A Fogdell-Hahn, D Rudzki, J Hillert, T Berger, M Reindl, and F Deisenhammer
Comparative study of four different assays for the detection of binding antibodies against interferon-{beta}
Multiple Sclerosis, July 1, 2008; 14(6): 830 - 836.
[Abstract] [PDF]

Home page
 NeurologyHome page
S. Malucchi, F. Gilli, M. Caldano, F. Marnetto, P. Valentino, L. Granieri, A. Sala, M. Capobianco, and A. Bertolotto
Predictive markers for response to interferon therapy in patients with multiple sclerosis
Neurology, March 25, 2008; 70(13_Part_2): 1119 - 1127.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
E. Wiesemann, M. Deb, C. Trebst, B. Hemmer, M. Stangel, and A. Windhagen
Effects of interferon-{beta} on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-{beta} treatment in patients with multiple sclerosis
Multiple Sclerosis, March 1, 2008; 14(2): 166 - 176.
[Abstract] [PDF]

Home page
 Mult SclerHome page
R. Farrell, R. Kapoor, S. Leary, P. Rudge, A. Thompson, D. Miller, and G. Giovannoni
Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta
Multiple Sclerosis, March 1, 2008; 14(2): 212 - 218.
[Abstract] [PDF]

Home page
 Mult SclerHome page
A.R. Pachner
Neutralizing anti-IFN{beta} antibodies: clarity and confusion
Multiple Sclerosis, November 1, 2007; 13(9): 1081 - 1082.
[PDF]

Home page
 Mult SclerHome page
F Gilli, F Hoffmann, A Sala, F Marnetto, M Caldano, P Valentino, L Kappos, A Bertolotto, and R L. Lindberg
Qualitative and quantitative analysis of antibody response against IFN{beta} in patients with multiple sclerosis
Multiple Sclerosis, November 1, 2006; 12(6): 738 - 746.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
K. Chadha, B. Weinstock-Guttman, R. Zivadinov, K. Bhasi, J. Muhitch, J. Feichter, M. Tamano-Blanco, N. Abdelrahman, J. Ambrus Sr, F. Munschauer, et al.
Interferon Inhibitory Activity in Patients With Multiple Sclerosis
Arch Neurol, November 1, 2006; 63(11): 1579 - 1584.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A. R. Pachner, K. Narayan, and E. Pak
Multiplex analysis of expression of three IFN{beta}-induced genes in antibody-positive MS patients
Neurology, February 14, 2006; 66(3): 444 - 446.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
C Ross, K M Clemmesen, P S Sorensen, N Koch-Henriksen, and K Bendtzen
Measuring and evaluating interferon b-induced antibodies in patients with multiple sclerosis
Multiple Sclerosis, February 1, 2006; 12(1): 39 - 46.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by AAN Enterprises, Inc.